Thomsen Pharma ApS: Financial statements 2022
CVR: 40620060
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Thomsen Pharma ApS (CVR 40620060) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -27,257 and a net result of DKK -539,510 compared with DKK 483,987 the year before. Equity in the 2022 report amounted to DKK 4,635,306. The solvency ratio was 99.1%.
- Gross Profit
- DKK -27,257
- Profit/Loss
- DKK -539,510
- Equity
- DKK 4,635,306
- Total Assets
- DKK 4,679,459
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -27K | -540K | 4.6M | - |
| 2021 | - | -19K | 484K | 5.2M | - |
| 2020 | - | -29K | 1.5M | 4.7M | - |
Official annual report
Keep an eye on Thomsen Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Thomsen Pharma ApS has published its annual report for 2021. Gross profit came to DKK -19,418, and the net result was DKK 483,987.
About Thomsen Pharma ApS
Thomsen Pharma ApS is a Danish company of the type Anpartsselskab based in Glamsbjerg, founded in 2019. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Mikael Søndergaard Thomsen. The company is owned by Mikael Søndergaard Thomsen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -14,978 and a net result of DKK -16,315 compared with DKK -4,005,382 the year before. Equity in the 2025 report amounted to DKK 607,713.